Kodiak Sciences Aktie [WKN DE: A2N6P0 / ISIN: US50015M1099]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Kodiak Sciences Inc Registered Shs

21.11.23		Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire)
14.11.23		Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
06.11.23		Kodiak's Phase 3 GLOW Study In Diabetic Retinopathy Meets Primary Goal (RTTNews)
06.11.23		Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regul... (PR Newswire)
02.11.23		KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY AN... (PR Newswire)
11.10.23		Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society (PR Newswire)
08.09.23		Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (PR Newswire)
07.09.23		New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vei... (PR Newswire)
14.08.23		Kodiak Sciences Inc. Q2 Loss decreases, but misses estimates (RTTNews)
14.08.23		Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
24.07.23		Kodiak Sciences To Discontinue Further Development Of Tarcocimab (RTTNews)
24.07.23		Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocim... (PR Newswire)
30.05.23		Kodiak Sciences to Present at Upcoming Investor Conferences (PR Newswire)
15.05.23		Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
21.04.23		Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting (PR Newswire)
13.04.23		Pre-market Movers: CXAI, SPWH, APVO, GFAI, AMBI… (RTTNews)
03.04.23		Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases (PR Newswire)
28.03.23		Kodiak Sciences Inc. Q4 Loss decreases, beats estimates (RTTNews)
28.03.23		Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights (PR Newswire)
09.02.23		Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneratio... (PR Newswire)
04.01.23		Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
16.11.22		Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference (PR Newswire)
09.11.22		Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights (PR Newswire)
22.09.22		Pre-market Movers: PRST, KOD, GRVY, BEAT, PULM… (RTTNews)
07.09.22		Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference (PR Newswire)
18.08.22		Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO) (PR Newswire)
09.08.22		Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights (PR Newswire)
08.08.22		Kodiak Sciences Reports Positive Topline Results From Phase 3 Study Of Tarcocimab Tedromer (RTTNews)
08.08.22		Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion (PR Newswire)
05.08.22		Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy (PR Newswire)
27.05.22		Kodiak Sciences to Present at the Jefferies Global Healthcare Conference (PR Newswire)
19.05.22		Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases (PR Newswire)
10.05.22		Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights (PR Newswire)
29.04.22		Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences (PR Newswire)
01.03.22		Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights (PR Newswire)
23.02.22		Pre-market Movers: TEN, KOD, REVB, GMBL, CSGP… (RTTNews)
23.02.22		Kodiak : Study Of KSI-301 On Neovascular Age-related Macular Degeneration Fails To Meet Primary Goal (RTTNews)
23.02.22		Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration (PR Newswire)
03.02.22		Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema (PR Newswire)
03.01.22		Kodiak Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference (PR Newswire)
16.12.21		Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion (PR Newswire)
09.11.21		Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights (PR Newswire)
08.11.21		Kodiak Sciences to Present at Upcoming Conferences (PR Newswire)
01.09.21		Kodiak Sciences Rolls Out New Long-Term Performance Incentive Plan - Quick Facts (RTTNews)
01.09.21		Kodiak Sciences Announces New Long-Term Performance Incentive Plan (PR Newswire)
31.08.21		Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (PR Newswire)
09.08.21		EARNINGS SUMMARY: Details of Kodiak Sciences Inc. Q2 Earnings Report (RTTNews)
09.08.21		Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights (PR Newswire)
10.05.21		Stock Alert: Kodiak Sciences Down 15% (RTTNews)
19.11.20		APVO Gets Buyout Offer, PFE/BNTX' COVID Shot 95% Effective, CORT Gets Favorable PTAB Ruling (RTTNews)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: Jetzt einsteigen und Millionär werden?

Pierer Mobility-Aktie mit zweistelligem Kurssprung: KTM AG wird fortgeführt - Eigenverwaltung bleibt

Bullishe Aussichten: Das erwartet JPMorgan für den Goldpreis in 2025

Mayr-Melnhof startet im kommenden Jahr Aktienrückkauf - Aktie gewinnt deutlich

Lilium-Aktie zündet Kursrakete: Lilium kann neuen Investor von sich überzeugen

Bitcoin Kurs Prognose: BTC verliert 10 Prozent, jetzt schnell verkaufen?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.12.2024 09:58
Kaufwert:	EUR
	Hinzufügen Speichern